Overview

A Study of Baricitinib (LY3009104) in Healthy Chinese Participants

Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to investigate the safety and tolerability of the study drug known as baricitinib in healthy Chinese participants. The study will measure how the body absorbs, breaks down and gets rid of baricitinib. The study will last about 20 days, not including screening. This study is for research purposes only, and is not intended to treat any medical condition.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company